AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18275580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 200
Study 18275580 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 200
Study 15694220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive communication with general practitioners (GPs) where consultants directly reported findings.
Number of subjects: 67
Study 15694220 — intervention group
Group type: COMPARATOR
Intervention: Standard practice where only inpatient referring physicians were informed of consultation findings.
Number of subjects: 67
Study 15694220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive communication with GPs.
Number of subjects: 67
Study 15694220 — intervention group
Group type: COMPARATOR
Intervention: Standard practice communication.
Number of subjects: 67
Study 15694220 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients beginning psychotherapy.
Number of subjects: 67
Study 15694220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of psychotherapy.
Number of subjects: 67
Study 15694220 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests for communication options by GPs.
Number of subjects: 67
Study 12913186 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-6002 (80 mg)
Number of subjects: 15
Study 12913186 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-6002
Number of subjects: 15
Study 12913186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10697970 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait plate inlays
Number of subjects: 18
Study 8788354 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management Course-Ankylosing Spondylitis (SMC-AS)
Number of subjects: 0
Study 1614072 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 36
Study 1614072 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 36
Study 1614072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (enalapril 5 mg + felodipine 5 mg)
Number of subjects: 36
Study 1614072 — intervention group
Group type: COMPARATOR
Intervention: Felodipine 5 mg added to enalapril 5 mg
Number of subjects: 36
Study 1614072 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5 mg added to felodipine 5 mg
Number of subjects: 36
Study 1614072 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 36
Study 1614072 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 36
Study 1614072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 36
Study 6599697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 3 X 10‐20 mg/day
Number of subjects: 10
Study 6599697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine + chlorthalidone, 25 to 50 mg/day
Number of subjects: 10
Study 6599697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31250880 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib at 125 mg daily, 3 weeks on/1 week off for 2 years
Number of subjects: 162
Study 31250880 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 162
Study 30256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reporting of occupational exposure to blood/body fluids
Number of subjects: 548
Study 30256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to blood/body fluids
Number of subjects: 548
Study 30256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-usage of safety protocols
Number of subjects: 548
Study 30256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support after injuries
Number of subjects: 548
Study 30256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Employer attention to needle-stick injuries
Number of subjects: 548
Study 30256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal and management factors
Number of subjects: 548
Study 27277115 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophyll c2 (0.7 mg daily for 12 weeks)
Number of subjects: 66
Study 27277115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 23684697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin augmentation
Number of subjects: 747
Study 23684697 — intervention group
Group type: COMPARATOR
Intervention: No oxytocin augmentation
Number of subjects: 747
Study 22858235 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg
Number of subjects: 426
Study 22858235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 20420787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 261
Study 20420787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 28 mg
Number of subjects: 261
Study 20420787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 20420787 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 261
Study 18611271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) administered twice at eight-week intervals during the transmission season.
Number of subjects: 262
Study 18611271 — intervention group
Group type: COMPARATOR
Intervention: No IPT (control group).
Number of subjects: 262
Study 18611271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) during the first 16 weeks of follow-up.
Number of subjects: 262
Study 18611271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) during the subsequent transmission season.
Number of subjects: 262
Study 18611271 — intervention group
Group type: COMPARATOR
Intervention: No IPT (control group) during the subsequent transmission season.
Number of subjects: 262
Study 18611271 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo response to treatment with SP.
Number of subjects: 262
Study 16292205 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 0
Study 16292205 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial fundoplication
Number of subjects: 0
Study 16292205 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fundoplication
Number of subjects: 0
Study 12124559 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with additional antioxidants (Allopurinol, vitamin E and C, N‐acetylcysteine, and mannitol)
Number of subjects: 22
Study 12124559 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 22
Study 10331884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoxia (FIO2 = 0.187; approximately 1,000 m)
Number of subjects: 19
Study 10331884 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 19
Study 10331884 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in SaO2 from normoxia to mild hypoxia
Number of subjects: 19
Study 10331884 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of SaO2 during maximal exercise in normoxia
Number of subjects: 19
Study 8696545 — intervention group
Group type: EXPERIMENTAL
Intervention: Groshong catheter (9.5F)
Number of subjects: 20
Study 8696545 — intervention group
Group type: COMPARATOR
Intervention: Hickman catheter (7F)
Number of subjects: 20
Study 1769413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg, twice daily for 10 days
Number of subjects: 330
Study 1769413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin 500 mg, twice daily for 10 days
Number of subjects: 330
Study 1769413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg, twice daily for 10 days
Number of subjects: 330
Study 7047707 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 34
Study 7047707 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 34
Study 30792052 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 210
Study 30792052 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 210
Study 28525302 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily (lower-dose group)
Number of subjects: 1689
Study 28525302 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily (higher-dose group)
Number of subjects: 1689
Study 28525302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1689
Study 25575502 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized diet and antismoking trial
Number of subjects: 16203
Study 25575502 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized drug treatment in mild-to-moderate hypertension
Number of subjects: 16203
Study 25575502 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking behavior and low total cholesterol
Number of subjects: 16203
Study 22882878 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided ads for participants high in assessment orientation
Number of subjects: 0
Study 22882878 — intervention group
Group type: COMPARATOR
Intervention: One-sided ads for participants high in locomotion orientation
Number of subjects: 0
Study 21248161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention ICUs
Number of subjects: 9269
Study 21248161 — intervention group
Group type: COMPARATOR
Intervention: Control ICUs
Number of subjects: 9269
Study 19321506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diamorphine plus intravenous morphine
Number of subjects: 22
Study 19321506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diamorphine plus oral morphine
Number of subjects: 22
Study 17125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 200 mg
Number of subjects: 42
Study 17125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 400 mg
Number of subjects: 42
Study 17125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg (single dose)
Number of subjects: 42
Study 17125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg (multiple doses for 8 days)
Number of subjects: 42
Study 17125605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 800 mg
Number of subjects: 42
Study 15552608 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednicarbate
Number of subjects: 0
Study 15552608 — intervention group
Group type: COMPARATOR
Intervention: Topical steroids
Number of subjects: 0
Study 11738277 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 400-microg folic acid supplement plus natural diet
Number of subjects: 126
Study 11738277 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary folate intake to 400 microg/day
Number of subjects: 126
Study 11738277 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus natural diet
Number of subjects: 126
Study 9286744 — intervention group
Group type: COMPARATOR
Intervention: Candy bar (C1: 280 kcal, 36 g CHO)
Number of subjects: 13
Study 9286744 — intervention group
Group type: COMPARATOR
Intervention: Fat-free fig bars (C2: 200 kcal, 44 g CHO)
Number of subjects: 13
Study 9286744 — intervention group
Group type: COMPARATOR
Intervention: Nonnutritive sweetened drink (C3: placebo)
Number of subjects: 13
Study 8343260 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG RIV (108 patients)
Number of subjects: 327
Study 8343260 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG Pasteur (109 patients)
Number of subjects: 327
Study 8343260 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only (110 patients)
Number of subjects: 327
Study 3520795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-15 mg prednisone daily
Number of subjects: 415
Study 3520795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 29424484 — intervention group
Group type: COMPARATOR
Intervention: Cardiogenic shock group (n=9)
Number of subjects: 61
Study 29424484 — intervention group
Group type: COMPARATOR
Intervention: Non-shock group (n=52)
Number of subjects: 61
Study 29424484 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=44)
Number of subjects: 61
Study 27062938 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST resolution before primary PCI
Number of subjects: 933
Study 27062938 — intervention group
Group type: COMPARATOR
Intervention: Continuous ST elevations before primary PCI
Number of subjects: 933
Study 26517404 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reading (tablet and computer display at 100% and 330% zoom levels)
Number of subjects: 50
Study 26517404 — intervention group
Group type: COMPARATOR
Intervention: Hard-copy reading (text in book position in silence and aloud, text pasted on the computer display)
Number of subjects: 50
Study 26517404 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reading
Number of subjects: 50
Study 26517404 — intervention group
Group type: COMPARATOR
Intervention: Hard-copy reading
Number of subjects: 50
Study 23745322 — intervention group
Group type: EXPERIMENTAL
Intervention: sL-selectin in patients with AMI
Number of subjects: 27
Study 23745322 — intervention group
Group type: EXPERIMENTAL
Intervention: sE-selectin in patients with AMI
Number of subjects: 27
Study 23745322 — intervention group
Group type: EXPERIMENTAL
Intervention: sP-selectin in patients with AMI
Number of subjects: 27
Study 23745322 — intervention group
Group type: COMPARATOR
Intervention: sE-selectin
Number of subjects: 27
Study 23745322 — intervention group
Group type: COMPARATOR
Intervention: sP-selectin
Number of subjects: 27
Study 23745322 — intervention group
Group type: COMPARATOR
Intervention: sL-selectin
Number of subjects: 27
Study 20656516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 20 mL administered once daily for 24 weeks
Number of subjects: 242
Study 20656516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 20656516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 242
Study 19473603 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 a.m.
Number of subjects: 18
Study 19473603 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 p.m.
Number of subjects: 18
Study 19473603 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 a.m. or p.m.
Number of subjects: 18
Study 17303249 — intervention group
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS) at 90% of individual motor threshold, 5 sessions of 20 Hz rTMS with 800 stimuli/day for 1 week.
Number of subjects: 19
Study 17303249 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group).
Number of subjects: 19
Study 15259895 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine alone (150 mg/day for 96 weeks)
Number of subjects: 80
Study 15259895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine plus interferon (10 MU three times a week for 24 weeks)
Number of subjects: 80
Study 15259895 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 80
Study 15259895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine plus interferon
Number of subjects: 80
Study 11703220 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 31
Study 11703220 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 31
Study 11703220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9390697 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy preterm neonates
Number of subjects: 100
Study 9390697 — intervention group
Group type: COMPARATOR
Intervention: Healthy term neonates
Number of subjects: 100
Study 8550858 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/co-polymer toothpaste
Number of subjects: 18
Study 8550858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride toothpaste
Number of subjects: 18
Study 8550858 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine rinse
Number of subjects: 18
Study 8550858 — intervention group
Group type: COMPARATOR
Intervention: Saline rinse
Number of subjects: 18
Study 2693849 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride (62 mmol intravenously during the initial 48 h)
Number of subjects: 130
Study 852337 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Isoniazid (5 to 6 mg/kg), Ethambutol (25 mg/kg), Rifampin (10 mg/kg) daily for 6 months
Number of subjects: 163
Study 852337 — intervention group
Group type: COMPARATOR
Intervention: Group 2: Same therapy as group 1 for 6 months, then Isoniazid (5 mg/kg three days per week) for an additional 6 months
Number of subjects: 163
Study 30476321 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop-mediated isothermal amplification (LAMP) assays for detection of APEC-associated virulence genes (sitA, traT, ompT)
Number of subjects: 6
Study 30476321 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP assays
Number of subjects: 6
Study 28189188 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 24
Study 25924592 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-based intervention including employee trainings and infrastructure changes
Number of subjects: 369
Study 25924592 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 369
Study 26386787 — intervention group
Group type: EXPERIMENTAL
Intervention: ABSORB BVS
Number of subjects: 2262
Study 26386787 — intervention group
Group type: COMPARATOR
Intervention: XIENCE everolimus-eluting stents (EES)
Number of subjects: 2262
Study 23880598 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus irinotecan
Number of subjects: 77
Study 19682100 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 136
Study 18519426 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 9977
Study 18519426 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 9977
Study 16619360 — intervention group
Group type: EXPERIMENTAL
Intervention: STA-1 (80 g/kg/day, administered twice daily for 6 months)
Number of subjects: 120
Study 16619360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (80 g/kg/day, administered twice daily for 6 months)
Number of subjects: 120
Study 12791625 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (234 mg cocoa flavanols and procyanidins/d)
Number of subjects: 32
Study 12791625 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (<= 6 mg cocoa flavanols and procyanidins/d)
Number of subjects: 32
Study 12791625 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 32
Study 12791625 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 32
Study 10983616 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg b.i.d. HFA-BDP
Number of subjects: 270
Study 10983616 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg b.i.d. HFA-BDP
Number of subjects: 270
Study 10983616 — intervention group
Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 270
Study 9153458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 100, 200, or 400 mg
Number of subjects: 14
Study 9153458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) titrated up to 400 mg
Number of subjects: 14
Study 9153458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7957540 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg dexfenfluramine taken with 250 ml water
Number of subjects: 0
Study 7957540 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg fluoxetine pretreatment at -8 h
Number of subjects: 0
Study 7957540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine daily for 14 days
Number of subjects: 0
Study 7957540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine alone 14 days after cessation of 14 days of fluoxetine treatment
Number of subjects: 0
Study 7957540 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 0
Study 3588052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.3 mg/kg initial dose, followed by 0.15 mg/kg every 4 hr for 12 hr)
Number of subjects: 14
Study 3588052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 14
Study 3588052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29089215 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIPA 'Full-On' physical activity program
Number of subjects: 8
Study 25344395 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with partial blood flow restriction (30% one-repetition-maximum)
Number of subjects: 13
Study 24297981 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted podiatric medical intervention (home-based foot and ankle exercises, assistance with safe footwear, provision of prefabricated foot orthoses)
Number of subjects: 153
Study 24297981 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted podiatric medical intervention
Number of subjects: 153
Study 20587703 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 238
Study 20587703 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 238
Study 20587703 — intervention group
Group type: COMPARATOR
Intervention: IL-7 tertile increase
Number of subjects: 238
Study 20587703 — intervention group
Group type: COMPARATOR
Intervention: IL-2 tertile increase
Number of subjects: 238
Study 18940401 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (6-month program with weekly training sessions)
Number of subjects: 17
Study 18940401 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised exercise (6-month program)
Number of subjects: 17
Study 16882538 — intervention group
Group type: EXPERIMENTAL
Intervention: UMTS base station-like exposure at 10 V/m
Number of subjects: 117
Study 16882538 — intervention group
Group type: COMPARATOR
Intervention: Control exposure (0 or 1 V/m)
Number of subjects: 117